22 Jun 2024 • Tirzepatide demonstrated significant improvements in apnea-hypopnea index (AHI), body weight, hypoxic burden, patient-reported sleep impairment, high-sensitivity C-reactive protein (hsCRP) concentration, and systolic blood pressure in individuals with moderate-to-severe obstructive sleep apnea and obesity compared to placebo.

• Two phase 3 trials were conducted, involving participants who were either not receiving positive airway pressure (PAP) treatment or already receiving PAP therapy. The participants were randomly assigned to receive either tirzepatide (10 or 15 mg) or placebo for 52 weeks. The primary endpoint was the change in AHI.

• The baseline characteristics showed similar mean Apnea-Hypopnea Index (AHI) values: 51.5 events per hour in trial 1 and 49.5 events per hour in trial 2.

• The mean body-mass index (BMI) at baseline was 39.1 in trial 1 and 38.7 in trial 2.

Gastrointestinal adverse events were the most commonly reported side effects.

Source:NEJM| Read full story